Allogene Therapeutics (ALLO) Net Cash Flow (2018 - 2026)

Allogene Therapeutics has reported Net Cash Flow for 9 years, with the latest figure at -$21.4 million in Q1 2026.

• Quarterly Net Cash Flow rose 34.75% year-over-year to -$21.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.1 million (down 41.5% YoY) and the FY2025 annual result came in at -$23.5 million, down 196.46% from the prior year.
• Net Cash Flow declined to -$21.4 million in Q1 2026 per ALLO's latest filing, from $13.9 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $119.6 million in Q2 2024 and troughed at -$119.4 million in Q3 2024.
• A 5-year average of -$8.4 million and a median of -$12.5 million in 2022 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 288.89% in 2023, down 294.36% in 2023.
• Over 5 years, Net Cash Flow stood at -$12.5 million in 2022, then surged by 211.69% to $13.9 million in 2023, then soared by 72.4% to $24.0 million in 2024, then sank by 42.15% to $13.9 million in 2025, then plunged by 254.11% to -$21.4 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$21.4 million, $13.9 million, and -$14.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.